This research reveals that agonistic anti-CD40 antibody therapy effectively eliminates immunosuppressive regulatory T (Treg) cells by forcing them to undergo a functional transformation. Within the tumor microenvironment, this treatment triggers a conversion process where Treg cells lose their Foxp3 expression and evolve into activated "ExTreg" cells. These reprogrammed cells adopt a Th1-like phenotype, characterized by the production of IFN-γ and increased antigen reactivity. This plasticity is driven by CD40-activated dendritic cells and the IL-12/IFN-γ cytokine axis, which also causes the cells to relocate to the tumor periphery. Ultimately, the study demonstrates that αCD40 immunotherapy can flip a pro-tumor suppressive state into a potent, localized anti-tumor immune response.

References:

• Maltez V I, Arora C, Gribbin K P, et al. Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment[J]. Immunity, 2026.